23 December 2020 - Deborah Wilkes
Angelini Pharma has hired Bayer’s Gabriele Ghirlanda as global access and value director with a place on the Italian company’s Executive Leadership Team.
Pierluigi Antonelli, Angelini Pharma’s chief executive officer, said Ghirlanda would “play a relevant, strategic role” by looking at investments the group planned to make in the fields of mental health, rare diseases and self-medication.
Ghirlanda joins from Bayer in Japan where he was head of market access – cardiovascular and nephrology. He also worked for Bayer in its home market of Germany as well as in the US.
Before joining Bayer in 2014, Ghirlanda spent three years with Boehringer Ingelheim in Italy and Germany.
He replaces global marketing head Fabio De Luca who led the global access function on an interim basis.
Ghirlanda reports directly to Antonelli.
About Angelini Pharma
Privately-held Angelini Pharma recorded sales of EUR903 million (USD1.11 billion) in 2019, of which half was generated outside its home market of Italy. It has a direct presence in 15 countries and its products are marketed in about 70 countries.
The company's consumer healthcare portfolio includes Amuchina disinfectants, Moment pain relievers, Tantum Verde oral care and sore throat products, and ThermaCare pain relievers.
Angelini Pharma is the pharmaceutical division of Angelini Group which has annual sales of around EUR1.70 billion.